SCHEMBL2155960

SCHEMBL2155960

Cc1cccc2c1C(=O)C(CN(C(=O)O)c1ccccc1)(CN(C(=O)O)c1ccccc1)CS2

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.35
TSHR P16473 2/20 0.35
GLA P06280 1/20 0.35
HTT P42858 3/20 0.31
CYP3A4 P08684 2/20 0.31
CYP2C9 P11712 2/20 0.31
CYP2C19 P33261 2/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
MYC P01106 1/20 0.31
ACHE P22303 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA7 P43166 1/20 0.31
CA9 Q16790 1/20 0.31
SIGMAR1 Q99720 1/20 0.31
SLC6A2 P23975 1/20 0.31
SLC6A4 P31645 1/20 0.31
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2155535 0.87 MAPT (0.38) HTTCYP3A4CYP2C19MEN1KMT2A
SCHEMBL2156840 0.84 TDP1 (0.36) ALDH1A1MEN1KMT2AGAA
SCHEMBL2155835 0.77 CA1 (0.38) MEN1KMT2AACHECA1CA2
SCHEMBL2157051 0.72 TSHR (0.39) ALDH1A1TSHRMEN1KMT2ASMN1; SMN2
SCHEMBL2157148 0.65 KDM4E (0.34) TP53
SCHEMBL28986134 0.60 TRPM8 (0.47) ALDH1A1TSHRGLAHTTCYP3A4
SCHEMBL13735234 0.58 ALDH1A1 (0.52) ALDH1A1TSHRGLAHTTCYP3A4
SCHEMBL3635003 0.58 ALDH1A1 (0.52) ALDH1A1TSHRGLAHTTCYP3A4
SCHEMBL11287043 0.58 ALDH1A1 (0.58) ALDH1A1TSHRGLAHTTCYP3A4
SCHEMBL380050 0.58 ALDH1A1 (0.76) ALDH1A1TSHRGLAHTTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973072-B2 Pain, eating disorders, neurodegenerative disorders, memory impairment; attention deficit syndrome, opioid tolerance, drug addiction; (4-oxothiochroman-3,3-diyl)bis(methylene)bis(3-(trifluoromethyl)benzoate for example GRUENENTHAL GMBH (DE) 2011-07-05 US claimed
US-20080161352-A1 Substituted Benzo-Condensed Cycloheptanone Derivatives and the Use Thereof for Medicament Production GRUENENTHAL GMBH (DE) 2008-07-03 US claimed
US-7973072-B2 Pain, eating disorders, neurodegenerative disorders, memory impairment; attention deficit syndrome, opioid tolerance, drug addiction; (4-oxothiochroman-3,3-diyl)bis(methylene)bis(3-(trifluoromethyl)benzoate for example GRUENENTHAL GMBH (DE) 2011-07-05 US disclosed
US-20080161352-A1 Substituted Benzo-Condensed Cycloheptanone Derivatives and the Use Thereof for Medicament Production GRUENENTHAL GMBH (DE) 2008-07-03 US disclosed
EP-1888555-A2 SUBSTITUTED BENZO-CONDENSED CYCLOHEXANONE DERIVATIVES AND THE USE THEREOF FOR MEDICAMENT PRODUCTION Grünenthal GmbH (DE) 2008-02-20 EP disclosed
WO-2006122771-A2 SUBSTITUTED BENZO-CONDENSED CYCLOHEXANONE DERIVATIVES AND THE USE THEREOF FOR MEDICAMENT PRODUCTION Grünenthal GmbH (DE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161352-A1 Substituted Benzo-Condensed Cycloheptanone Derivatives and the Use Thereof for Medicament Production BCKDK, SYMPK, DHPS ALDH1A1 1598/4885TSHR 4824/4885GLA 4168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.